세계 Drug Discovery 분야 인공지능(AI) 시장은 2023-2030년 연평균 27.2%의 성장률로 성장하여 2030년까지 89억 5,000만 달러에 달할 것으로 예상됩니다.
이 보고서는 광범위한 2차 및 1차 조사, 시장 시나리오에 대한 심층 분석을 통해 주요 산업 촉진요인, 저해요인, 도전 과제 및 기회 분석으로 구성되어 있습니다.
이 시장의 성장은 Drug Discovery 시간 단축에 대한 관심 증가, Drug Discovery에 있어 AI의 신흥 시장 확대, 만성 질환의 유병률 증가, Drug Discovery 및 시장 개척 과정을 가속화하기 위한 공동 연구 및 파트너십 증가에 기인하는 것으로 보입니다. AI를 신약개발에 통합하기 위한 자원의 제약이 이 분야 시장 확대에 큰 걸림돌로 작용하고 있습니다.
또한, 신흥 경제국의 성장과 R&D에 대한 투자 증가는 이 시장의 이해관계자들에게 유리한 기회를 창출할 것으로 예상됩니다. 그러나 가용한 데이터 세트가 제한적이라는 점은 시장 성장에 영향을 미치는 큰 도전 과제입니다.
Artificial Intelligence in Drug Discovery Market Size, Share, Forecast, & Trends Analysis by Offering (Software, Service), Application (Target Discovery, Testing), Therapy Area (Oncology, Cardiology), Deployment, End User-Global Forecast to 2030
The global artificial intelligence in drug discovery market is projected to reach $8.95 billion by 2030 at a CAGR of 27.2% from 2023 to 2030.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.
The growth of this market can be attributed to the rising focus on reducing turnaround time in drug discovery, growing applications of AI in drug discovery, rising prevalence of chronic diseases, and rising collaborations & partnerships to accelerate the process of drug discovery and development. The constrained resource availability for integrating AI into drug discovery poses a significant impediment to market expansion in this sector.
Moreover, the growth of emerging economies and increased investments in research & development are anticipated to create lucrative opportunities for stakeholders in this market. However, limited availability of data sets are major challenges impacting market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2020-2023). The key players operating in the global artificial intelligence in drug discovery market are Microsoft Corporation (U.S.), Exscientia plc (U.K.), NVIDIA Corporation (U.S.), Schrodinger, LLC (U.S.), Atomwise, Inc. (U.S.), BenevolentAI Limited (U.K.), Deep Genomics Incorporated (Canada), InSilico Medicine (U.S.), Cloud Pharmaceuticals, Inc. (U.S.), and Standigm Inc. (South Korea).
Among all the offerings studied in this report, in 2023, the software segment is expected to account for the largest share of the AI in drug discovery market. AI in drug discovery software is used for faster, efficient, and cost-effective drug discovery and enhanced clinical trials. Thus, the growing interest of pharmaceutical companies in developing novel therapies has increased the adoption of AI in drug discovery software.
Among all the deployment modes studied in this report, the cloud-based segment is projected to register the highest CAGR over the forecast period. The demand for cloud-based and web-based platforms is growing due to the benefits of cloud-based models in terms of security, flexibility, high-capacity data storage, quick accessibility, and cost-effectiveness.
Among all the therapeutic areas studied in this report, in 2023, the oncology segment is expected to account for the largest share of the global AI in drug discovery market. Numerous collaborations between drug discovery and AI companies are bolstering the significant market share of this segment. For instance, in November 2022, The University of Texas MD Anderson Cancer Center (U.S.) and Exscientia plc (U.K.) entered a strategic collaboration to combine the drug discovery & development expertise of MD Anderson with the patient-centric artificial intelligence (AI) capabilities of Exscientia, to boost the development of novel small-molecule oncology therapies. Additionally, in November 2021, Sanofi (France) announced an equity investment of USD 180 million in Owkin (U.S.), an AI and precision medicine company, aimed at advancing its oncology pipeline.
Among all the applications studied in this report, in 2023, the lead compound identification segment is expected to account for the largest share of the global AI in drug discovery market. Identifying lead compounds is a pivotal stage in drug discovery, where crucial properties like selectivity and potency are determined before advancing to clinical studies. Integrating AI can streamline pre-clinical development timelines, optimizing resource allocation effectively. Therefore, the utilization of AI in this phase of drug discovery is pivotal, contributing significantly to the large market share of this sector.
Among all end users studied in this report, in 2023, the pharmaceutical & biopharmaceutical companies segment is expected to account for the largest share of the global AI in drug discovery market. The high prevalence of chronic and infectious diseases, high pressure on the pharmaceutical, and biotechnology companies, to bring effective therapies early to the market, and combined benefits of AI algorithms in facilitating smooth drug discovery processes are key factors contributing to the significant market share of this segment.
An in-depth analysis of the geographical scenario of the global artificial intelligence in drug discovery market provides detailed qualitative and quantitative insights into the five major regions (North America, Europe, Asia-Pacific, Latin America, and the Middle-East & Africa), along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the artificial intelligence in drug discovery market. In North America, in 2023, the U.S. is expected to account for the largest share of the artificial intelligence in drug discovery market. The large share of this regional market is attributed to increasing public and private investments in drug discovery, and the high adoption of AI solutions in drug discovery. The presence of key AI companies and pharmaceutical companies such as Abbott Laboratories (U.S) and Pfizer Inc. (U.S) also support the large share of this market.
Artificial Intelligence in Drug Discovery Market Assessment-by Offering
Artificial Intelligence in Drug Discovery Market Assessment-by Deployment Mode
Artificial Intelligence in Drug Discovery Market Assessment-by Application
Artificial Intelligence in Drug Discovery Market Assessment-by Therapeutic Area
Note: Other therapeutic areas include infectious diseases and rare diseases.
Artificial Intelligence in Drug Discovery Market Assessment-by End Users
Artificial intelligence in Drug Discovery Market Assessment-by Geography